FTX and myeloid sarcoma: As depicted in Fig. 4 A-C, lncRNA Ftx expression showed no statistically significant differences between the control group and the various MS subtypes: MS (p = 0.4599), RRMS (p = 0.8499), and SPMS (p = 0.2705).